135 related articles for article (PubMed ID: 20488473)
1. XPC epigenetic silence coupled with p53 alteration has a significant impact on bladder cancer outcome.
Yang J; Xu Z; Li J; Zhang R; Zhang G; Ji H; Song B; Chen Z
J Urol; 2010 Jul; 184(1):336-43. PubMed ID: 20488473
[TBL] [Abstract][Full Text] [Related]
2. Reduced XPC messenger RNA level may predict a poor outcome of patients with nonsmall cell lung cancer.
Wu YH; Cheng YW; Chang JT; Wu TC; Chen CY; Lee H
Cancer; 2007 Jul; 110(1):215-23. PubMed ID: 17508409
[TBL] [Abstract][Full Text] [Related]
3. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
Krüger S; Lange I; Kausch I; Feller AC
Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
Dekairelle AF; Tombal B; Cosyns JP; Gala JL
Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
[TBL] [Abstract][Full Text] [Related]
7. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
[TBL] [Abstract][Full Text] [Related]
8. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
9. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
10. [Expression of cyclooxygenase-2 in human transitional cell bladder carcinomas].
Zhan J; Tang XD
Ai Zheng; 2002 Nov; 21(11):1212-6. PubMed ID: 12526218
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast.
Schlichtholz B; Presler M; Matuszewski M
Carcinogenesis; 2004 Dec; 25(12):2319-23. PubMed ID: 15308588
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
[TBL] [Abstract][Full Text] [Related]
13. Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer.
Takihana Y; Tsuchida T; Fukasawa M; Araki I; Tanabe N; Takeda M
Int J Urol; 2006 Apr; 13(4):401-8. PubMed ID: 16734859
[TBL] [Abstract][Full Text] [Related]
14. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers.
Migaldi M; Sgambato A; Garagnani L; Ardito R; Ferrari P; De Gaetani C; Cittadini A; Trentini GP
Clin Cancer Res; 2000 Aug; 6(8):3131-8. PubMed ID: 10955794
[TBL] [Abstract][Full Text] [Related]
15. p53 and RB expression predict progression in T1 bladder cancer.
Grossman HB; Liebert M; Antelo M; Dinney CP; Hu SX; Palmer JL; Benedict WF
Clin Cancer Res; 1998 Apr; 4(4):829-34. PubMed ID: 9563875
[TBL] [Abstract][Full Text] [Related]
16. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
[TBL] [Abstract][Full Text] [Related]
17. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma.
Tiguert R; Bianco FJ; Oskanian P; Li Y; Grignon DJ; Wood DP; Pontes JE; Sarkar FH
J Urol; 2001 Dec; 166(6):2155-60. PubMed ID: 11696726
[TBL] [Abstract][Full Text] [Related]
18. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
19. [Comparative study of P 53, Bcl-2, and C-erbB-2 expression in low-grade papillary bladder tumors].
Ramos Soler D; Navarro Fos S; Villamón Fort R; Gil Salom M; Llombart Bosch A
Arch Esp Urol; 2003 Apr; 56(3):277-85. PubMed ID: 12768988
[TBL] [Abstract][Full Text] [Related]
20. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients.
Friedrich MG; Weisenberger DJ; Cheng JC; Chandrasoma S; Siegmund KD; Gonzalgo ML; Toma MI; Huland H; Yoo C; Tsai YC; Nichols PW; Bochner BH; Jones PA; Liang G
Clin Cancer Res; 2004 Nov; 10(22):7457-65. PubMed ID: 15569975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
